-
1.发明授权TREATMENT OF STRESS AND PRECONDITIONING AGAINST STRESS 有权BEHANDLUNG VON STRESS UND VORBEHANDLNG GEGEN STRESS
公开(公告)号：EP1011696B1
公开(公告)日：2003-11-12
申请号：EP98943592.0
申请日：1998-09-11
申请人： Vasogen Ireland Limited , Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal
发明人： HAMET, Pavel , TREMBLAY, Johanne
CPC分类号： A61K35/14 , A61K33/40 , A61K41/0004 , A61M1/32 , A61M1/3681 , A61M1/3683 , A61M1/369 , A61M2205/053
摘要： Symptoms of stress such as elevated blood pressure in mammals are treated, and mammalian bodies are preconditioned to manifest reduced adverse reactions to subsequently encountered stresses, by injecting into the mammalian patient a small quantity of the patient's own blood which has been previously extracted and subjected extracorporeally to at least one stressor, such as ultraviolet radiation, an oxidative environment, ozone-oxygen and mild heating, especially infra-red radiation causing mild heating. Particularly beneficial combinations of stressors are simultaneous applications of UV radiation and an ozone-oxygen gas mixture bubbled through the blood sample to provide the oxidative environment, or simultaneous application of UV radiation, ozone-oxygen gas mixtures and mild heating. One specific use of the invention is in preconditioning against ischemic-reperfusion injury, e.g. prior to surgery.
摘要翻译： 治疗哺乳动物压力升高的症状，哺乳动物身体预处理，以便对随后遇到的压力表现出减少的不良反应，通过向哺乳动物患者注入少量先前已提取并经受体外治疗的患者自己的血液 至少一种应激源，例如紫外线辐射，氧化环境，臭氧氧和温和加热，特别是导致温和加热的红外线辐射。 压力源的特别有益的组合是同时应用UV辐射和鼓泡通过血液样品的臭氧 - 氧气混合物以提供氧化环境，或同时施加UV辐射，臭氧 - 氧气混合物和温和加热。 本发明的一个具体用途是对缺血再灌注损伤进行预处理，例如， 手术前。
-
2.发明公开ANTI-APOPTOTIC COMPOSITIONS COMPRISING THE R1 SUBUNIT OF HERPES SIMPLEX VIRUS RIBONUCLEOTIDE REDUCTASE OR ITS N-TERMINAL PORTION; AND USES THEREOF 审中-公开抗凋亡组合物，其单纯疱疹病毒核糖核苷酸还原酶的R1亚基或N末端含有并及其用途
公开(公告)号：EP1100533A2
公开(公告)日：2001-05-23
申请号：EP99932585.5
申请日：1999-07-23
发明人： LANGELIER, Yves , MASSIE, Bernard
CPC分类号： A61K38/44 , A61K48/00 , C07K14/005 , C12N2710/16622
摘要： The R1 subunit of herpes simplex virus (HSV) ribonucleotide reductase, which is expressed very early after viral reactivation, possesses an N-terminal domain of about 350 amino acids of unknown function. Using an adenovirus (Ad) inducible system we had demonstrated that a complete deletion of this domain produces a cytotoxic protein. We now report that apoptotic death induced by this truncated R1 could be completely prevented by coexpression of the full-length R1. The R1 antiapoptotic activity was further substantiated by showing that expression of this protein at low level can completely block apoptosis induced either by TNF-receptor family triggering in the presence of cycloheximide (CHX) or by Fas-L coexpression with an Ad recombinant. In both cases, the protection was lost when inhibiting tTA function with the tetracycline analog doxycycline shut down R1 expression. A level of R1 of 0.005 % total cell protein was sufficient for half-maximal protection against TNFα+CHX. By monitoring caspase 8 activation either by immunoblot with an antiserum visualizing the inactive 56-kDa proform and the active 18-kDa species or by an in vitro assay using ETD-AFC as caspase 8 specific fluorescent substrate, we found that the strong activation of caspase 8 induced either by TNF-α+CHX or Fas-L expression was prevented by the R1 protein. Finally, using an HSV-1 R1 deletion mutant, ICP6Δ, we obtained direct evidence for the importance of HSV-R1 in protecting HSV-infected cells against cytokine-induced apoptosis. These results show that, in addition to its reductase function which is essential for viral reactivation, the HSV R1 could contribute to viral propagation by preventing apoptosis induced by the immune system. The N-terminal domain by itself is as anti-apoptotic as the whole RI protein. An anti-apoptotic agent and a composition derived therefrom are described and claimed.
-
3.发明公开METHOD OF ASSAYING COMPOUNDS WHICH AFFECT THE ACTIVITY OF G PROTEIN-COUPLED RECEPTORS BASED ON MEASUREMENT OF RECEPTOR OLIGOMERIZATION 失效对受体低聚基于测量的方法的活性偶联受体BEEIFLUSSEN G蛋白化合物的试验
公开(公告)号：EP0939902A2
公开(公告)日：1999-09-08
申请号：EP97928072.0
申请日：1997-06-30
IPC分类号： G01N33
CPC分类号： G01N33/94 , G01N2333/726
摘要： This invention is a new method of assaying compounds that modulate the activity of G protein-coupled receptors based on measurement of changes in the relative proportions of monomeric to multimeric receptor polypeptides. More specifically, techniques are described herein which permit the prediction of the pharmacological efficacy of drug candidates based solely on the ability of the candidate compounds to alter the ratio of receptor monomer to homo-oligomeric forms of the receptor. This method provides a novel means of assaying compounds as potential therapeutic drugs at G protein-coupled receptors which is greatly simplified and more generally applicable than existing methods.
-
公开(公告)号：EP1146885A1
公开(公告)日：2001-10-24
申请号：EP00900465.6
申请日：2000-01-11
申请人： Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal , Vasogen Ireland Limited
发明人： HAMET, Pavel,c/o Chum, Pavilion Hotel-Dieu , TREMBLAY, Johanne,c/o Chum, Pavilion Hotel-Dieu , DESROSIER, Christine , CHENG, Huifang
IPC分类号： A61K35/14
CPC分类号： A61K35/14 , A61K41/0019 , A61M1/0281 , A61M1/3681 , A61M1/3683 , A61M1/3687 , A61M1/369 , A61M2202/0216 , A61M2205/053
摘要： Apoptosis and/or necrosis related disorders in the mammalian body, namely radiation exposure disorders, chemical exposure and ingestion disorders, neurological disorders and physical trauma disorders, are treated, and their onset is counteracted by pre-conditioning, by extracting from the mammalian body an aliquot of blood, subjecting the extracted aliquot, ex vivo, to an oxidative stressor such as exposure to ozone gas, a temperature stressor, i.e. temperatures above or below body temperatures, and ultraviolet light, and re-injecting the treated blood aliquot into the mammalian body. The treatment has the effect of decreasing apoptosis/necrosis in the body, and of pre-conditioning the body better to withstand subsequently encountered apoptosis-inducing events.
摘要翻译： 治疗哺乳动物身体中的细胞凋亡和/或坏死相关疾病，即放射线暴露障碍，化学暴露和摄入障碍，神经障碍和身体创伤障碍，并通过预处理来抵消它们的发作，通过从哺乳动物体内提取 将血液等分试样，离体将经过提取的等分试样经受氧化应激源，例如暴露于臭氧气体，温度胁迫器，即高于或低于体温的温度和紫外线，并将经处理的血液等分试样重新注入哺乳动物 身体。 该治疗具有减少身体凋亡/坏死的作用，并且更好地预处理身体以抵抗随后遇到的凋亡诱导事件。
-
5.发明公开PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS AFFECTING THE ACTIVITY OF G-PROTEIN-COUPLED RECEPTORS BY ALTERING RECEPTOR OLIGOMERIZATION 失效肽和肽模拟物分子中的变化IN受体OLIGOMERIZATIONSVERFAHREN G蛋白偶联受体阻碍活性
公开(公告)号：EP0910640A2
公开(公告)日：1999-04-28
申请号：EP97933814.0
申请日：1997-07-01
CPC分类号： C07K7/08 , A61K38/00 , C07K14/705 , C07K14/70571 , C07K14/7158 , C07K14/723
摘要： This invention relates to peptides and peptidomimetic compounds that modulate the function of G-protein-coupled receptors by affecting the ratio of receptor monomer to homo-oligomeric forms. Novel short peptides of a preferred length of up to about 15-20 amino acid residues are modeled on transmembrane domains of G-protein-coupled receptors, whose activities are affected by the formation of oligomers. These novel peptides and peptidomimetic compounds can be used to selectively affect the activity of G-protein-coupling receptors, thereby functioning as potential therapeutic drugs, etc.. A preferred peptide is GIIMGTFTLCWLPFFIVNIV.
-
6.发明公开
公开(公告)号：EP0901525A2
公开(公告)日：1999-03-17
申请号：EP97916291.0
申请日：1997-04-21
CPC分类号： C07K14/70571 , A61K38/00
摘要： This invention relates to peptides and peptidomimetic compounds that act as antagonists against G protein-coupled receptors (GPCRs). Novel short peptides, derived from the transmembrane domains of GPCRs, ranging in size from about 15-20 amino acid residues, can be used as model peptides (peptide-leads) to design novel peptides and peptidiomimetic compounds that antagonize the activity of the same or closely related GPCRs from which they are derived. A lead peptide which may also be a preferred peptide antagonist for the human β2-adrenergic receptor is NH2-GIIMGTFTLCWLPFFIVNIVH-COOH.
-
公开(公告)号：EP1713398A1
公开(公告)日：2006-10-25
申请号：EP05706474.3
申请日：2005-02-09
申请人： UNIVERSITE DE MONTREAL , Centre Hospitalier De L'Universite de Montreal , UNIVERSITE JOSEPH FOURIER (GRENOBLE 1)
CPC分类号： A61B5/02007 , A61B5/0066 , A61B8/08 , A61B8/0891 , A61B8/485 , A61B8/587 , G06T7/0012 , G06T7/20 , G06T2207/10132 , G06T2207/30101 , G06T2207/30241
摘要： The method for vascular elastography comprises: i) obtaining a sequence of radio-frequency (RF) images including pre-tissue-motion and post-tissue-motion images in digital form of a vessel delimited by a vascular wall; the pre-tissue-motion and post-tissue-motion images being representative of first and second time-delayed configuration, of the whole vessel; ii) partitioning both the pre-tissue-motion and post-tissue-motion images within the vascular wall into corresponding data windows; approximating a trajectory between the pre- and post-tissue-motion for corresponding data windows; and using the trajectory for each data window to compute the full strain tensor in each data window, which allow determining the Von Mises coefficient. The method can be adapted for non-invasive vascular elastography (NIVE), for non-invasive vascular micro-elastography (MicroNIVE) on small vessels, and for endovascular elastography (EVE).
-
8.发明公开USES OF OUABAIN AND OUABAIN-LIKE MOLECULES IN APOPTOSIS RELATED PATHOLOGIES 审中-公开哇巴因类似的分子的细胞凋亡相关疾病中的用途
公开(公告)号：EP1196177A2
公开(公告)日：2002-04-17
申请号：EP00938367.0
申请日：2000-06-02
IPC分类号： A61K31/704 , A61K31/7042 , A61P39/00 , A61P9/00 , A61P9/10 , A61P9/14 , A61P13/12 , A61P25/00 , A61P25/28
CPC分类号： A61K31/7048 , A61K31/704 , A61K31/7042
摘要： The inventation describes the use of ouabain or an ouabain-like molecule for protection against apoptosis in various organs or tissues. The compound acts by inhibiting the Na+, k+ pump, thereby inverting the physiologically low intracellular Na+/k+ ratio required for progression of apoptosis (e.g. in VSMC). Therefore, the molecule can be used to treat disorders of diseases due to increased apoptosis, such as cardiopathies myocardial ischemia/angina, infarct or infection, congestive heart failure, cns or neurodegenerative disorders, trauma, reperfusion injury, severe burn or renal failure.
-
公开(公告)号：EP1011696A1
公开(公告)日：2000-06-28
申请号：EP98943592.0
申请日：1998-09-11
申请人： Vasogen Ireland Limited , Centre De Recherche Du Centre Hospitalier De L'Universite De Montreal
发明人： HAMET, Pavel , TREMBLAY, Johanne
CPC分类号： A61K35/14 , A61K33/40 , A61K41/0004 , A61M1/32 , A61M1/3681 , A61M1/3683 , A61M1/369 , A61M2205/053
摘要： Symptoms of stress such as elevated blood pressure in mammals are treated, and mammalian bodies are preconditioned to manifest reduced adverse reactions to subsequently encountered stresses, by injecting into the mammalian patient a small quantity of the patient's own blood which has been previously extracted and subjected extracorporeally to at least one stressor, such as ultraviolet radiation, an oxidative environment, ozone-oxygen and mild heating, especially infra-red radiation causing mild heating. Particularly beneficial combinations of stressors are simultaneous applications of UV radiation and an ozone-oxygen gas mixture bubbled through the blood sample to provide the oxidative environment, or simultaneous application of UV radiation, ozone-oxygen gas mixtures and mild heating. One specific use of the invention is in preconditioning against ischemic-reperfusion injury, e.g. prior to surgery.
-
公开(公告)号：EP2545378A1
公开(公告)日：2013-01-16
申请号：EP11752787.9
申请日：2011-03-08
IPC分类号： G01N33/564 , G01N33/68
CPC分类号： G01N33/564 , G01N2333/4722 , G01N2800/245
摘要： A method for the prediction of the risk and/or the diagnosis of vascular damage such as acute vascular rejection in a subject, based on the determination of anti-LG3 antibodies levels in a sample from the subject, is disclosed.
摘要翻译： 公开了基于确定来自受试者的样品中的抗LG3抗体水平来预测受试者中血管损伤（例如急性血管排斥）的风险和/或诊断的方法。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.013 秒)
